When platelets reach a million: insights from hematologists
Annals of Hematology · 26.09.2026 · 105 (11)
DOI: 10.1007/s00277-026-07183-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 26.09.2026. Verfasst von Özge Sönmez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cerrahpaşa Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University-Cerrahpaşa, Fatih, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Thrombocythemia, Essential, Thrombocytosis, Blood Platelets, Hematology. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The management of patients with essential thrombocythemia (ET) and extreme thrombocytosis (ExT) remains plagued by several unresolved issues. Therefore, we conducted a web-based survey to better understand hematologists' clinical approaches to ExT and to compare them with responses generated by artificial intelligence (AI) programs. A total of 56 hematologists participated. Cytoreductive treatment was preferred by 41.1% of respondents at a platelet threshold of ≥ 1000 × 10⁹/L and by 83.9% at ≥ 1500 × 10⁹/L. Assessment of vWF: RCo at diagnosis was reported by 78.6% of hematologists. In the presence of cardiovascular risk factors and the absence of acquired von Willebrand disease (vWD), aspirin therapy was favored by 91.1% and 78.6% of respondents for platelet counts ≥ 1000 × 10⁹/L and ≥ 1500 × 10⁹/L, respectively. Prevention of thrombosis, prevention of bleeding, and symptom control were cited with similar frequencies as reasons for initiating cytoreductive treatment. Artificial intelligence (AI)-generated recommendations supported vWF testing, favored cytoreductive treatment, particularly at platelet counts ≥ 1500 × 10⁹/L, and generally recommended aspirin only for patients with platelet counts ≥ 1000 × 10⁹/L in the absence of acquired vWD. Overall, ExT appeared to be an important driver of treatment decisions, particularly at platelet counts ≥ 1500 × 10⁹/L. Comparisons with AI-generated recommendations revealed few differences in treatment approaches across some clinical scenarios, supporting the exploratory nature of the AI analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cerrahpaşa Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University-Cerrahpaşa, Fatih, Istanbul, Türkiye.
- Cerrahpaşa Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University-Cerrahpaşa, Fatih, Istanbul, Türkiye. emre.eskazan@iuc.edu.tr.
- Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye. emre.eskazan@iuc.edu.tr.
Zitieren
APA
Sönmez, Ö., & Eşkazan, A. E. (2026). When platelets reach a million: insights from hematologists. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07183-x
Vancouver
Sönmez Ö, Eşkazan AE. When platelets reach a million: insights from hematologists. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07183-x
BibTeX
@article{Snmez2026,
author = {Sönmez, Özge and Eşkazan, Ahmet Emre},
title = {When platelets reach a million: insights from hematologists},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {11},
doi = {10.1007/s00277-026-07183-x}
}
EUVIMED